Introduction
Families with inherited breast and ovarian cancers frequently have mutations of the breast cancer susceptibility gene BRCA1 (Futreal et al., 1994) . The BRCA1 gene encodes a 220 kDa nuclear protein whose precise biochemical function remains unclear, although multiple functions have been suggested. These include DNA repair, growth inhibition and as a transcription factor (Aprelikova et al., 1999; Chapman and Verma, 1996; Chen et al., 1999; Haile and Parvin, 1999) . BRCA1 does not share any signi®cant homology to any known proteins. However it does contain several well-de®ned functional domains: an N-terminal RING ®nger domain important for protein ± protein interactions, including BARD1 and ATF1 (Houvras et al., 2000; Wu et al., 1996) ; a domain in the middle of BRCA1 associates with the DNA repair protein RAD51 (Scully et al., 1997) ; and the C-terminal contains two repeats of the BRCT domains. These BRCT domains appear to be involved in many of the functions ascribed to BRCA1.
Various studies have suggested a role for BRCA1 in the transcriptional activation of speci®c genes. Overexpression of wild-type BRCA1, but not tumor-derived mutants, results in a G1 cell cycle arrest mediated via the transcriptional activation of p21
Waf1/Cip1 in a p53-independent manner (Somasundaram et al., 1997) . However, BRCA1 has also been shown to co-activate the transcription of p53-regulated genes (Jin et al., 2000; Ouchi et al., 1998; Zhang et al., 1998) . These studies demonstrated that the C-terminus of BRCA1 is required for its function as a transcriptional activator. Two transactivation domains have been identi®ed in the C-terminus; one localized to amino acids 1560 ± 1863 including the BRCT domain; and more recently, a second transactivation domain was mapped to amino acids 1293 ± 1558 (Chapman and Verma, 1996; Hu et al., 2000) . Most cancer-predisposing mutations of BRCA1 results in gross truncation of the protein, thus disrupting the C-terminal transactivation domain and compromising this function of BRCA1.
Although BRCA1 has been shown to inhibit cell cycle progression via activation of p21
Waf1/Cip1 , this may not be the only mechanism growth inhibition by BRCA1.
Cell cycle progression is governed by a family of cyclin-dependent kinases, whose activity is regulated by phosphorylation, activated by cyclin binding and inhibited by various inhibitors, such as p21 Waf1/Cip1 and p27
Kip1 (Sherr, 1994; Sherr and Roberts, 1999) . The p27
Kip1 was demonstrated to bind to cyclin E-ckd2 complexes and inhibit the kinase function of cdk2 (Polyak et al., 1994) . A number of other functions have been suggested for p27
Kip1 including as a promoter of apoptosis, as a regulator of drug resistance in solid tumors and having a role in cell dierentiation (Katayose et al., 1997; St. Croix et al., 1996; Durana et al., 1997; Onishi and Hruska, 1997) . A number of studies have also examined p27
Kip1 expression in a series of tumors to determine if there is any diagnostic or prognostic signi®cance. It has been shown that p27
Kip1 protein decreases during tumor development and progression in breast, colon, prostate and ovarian cancers (Catzevalos et al., 1997; Ciaparrone et al., 1998; Cordon-Cardo et al., 1998; Masciullo et al., 1999) . The demonstration that even a heterozygous reduction of p27 Kip1 leads to spontaneous and radiation-induced tumors in mice further suggests that p27
Kip1 may play an important role in neoplastic progression (Fero et al., 1998) .
Previously we observed a correlation between the expression of BRCA1 and p27
Kip1 in a series of breast cancer cell lines (Elstner et al., 2002) . In this study, we have analysed the p27 Kip1 promoter in order to determine if this cyclin-dependent kinase inhibitor (CDKI) is transcriptionally activated by BRCA1 and the elements important for this activity.
Results

Transcriptional activation of the p27
Kip1 promoter
By transient transfections we examined the eect of BRCA1 on both mouse and human p27 Kip1 promoter reporter gene expression in COS, MCF7 breast cancer and HCT116 colon cancer cells (Figure 1a ,b). pCR3-BRCA1 activated the mouse p27
Kip1 promoter by 10-fold in COS cells and ®vefold in MCF7 and HCT116 cells (Figure 1b) , as compared to the pCR3 vector. Similar fold activation was also observed for the human p27
Kip1 promoter in these cell lines (data not shown).
BRCA1 is frequently mutated in hereditary breast and ovarian cancer. The consequence of these mutations is the generation of a truncated protein which is either non-functional or unstable. Therefore to investigate further the speci®city of p27 Kip1 induction by BRCA1 we studied the eect of various synthetic and tumor-associated BRCA1 mutants on p27
Kip1 promoter reporter gene expression (Figure 2a ). In these reporter assays four dierent tumor-associated BRCA1 mutants and a synthetic BRCA1 mutant (del 500 ± 1863) were unable signi®cantly to transactivate the p27 Kip1 promoter reporter compared to the wildtype BRCA1 (Figure 2b ). However, a second synthetic mutant lacking only the RAD51-interacting domain but with a functional nuclear localization signal and Cterminal transactivation domain, BRCA1 (del 515 ± 1091), was able to transactivate the p27
Kip1 promoter nearly as eciently as the wild-type BRCA1 ( Figure  2b ).
We next investigated the possible mechanism for regulation of p27
Kip1 by BRCA1. It has been shown in other studies that the regulation of expression of p27
Kip1 is primarily via post-translational mechanisms.
Western immunoblot analysis of HCT116 cells demonstrated that endogenous p27
Kip1 protein expression was up-regulated by wild-type BRCA1 but not by either the control vector pCR3 or a mutated BRCA1 (Gln1756insC) (Figure 3a) . Wild-type and mutant forms of BRCA1 were expressed at similar levels Kip1 promoter luciferase promoter. The 3' boundary is 178 bp downstream of the translation start site. (b) COS, MCF7 and HCT116 were cotransfected with p27ptr-luc and either pCR3 or pCR3-BRCA1 and luciferase activity was measured 48 h later. These results represent three independent experiments. Results are shown as RLU which is the ratio of the luciferase units observed for the promoter construct compared to that seen for the pRL-SV40 To determine the mechanism for this up-regulation (transcriptional versus post-translational) we isolated RNA from cells transiently transfected with control vector, wild-type BRCA1 or mutated BRCA1 and proceeded with reverse transcription-PCR. PCR for BRCA1 used primers for exons 14 and 15 so that both wild-type and mutant BRCA1 could be detected. At 25 cycles a PCR product for both BRCA1 constructs was observed ( Figure 3b ). However, at 30 cycles a PCR product for p27
Kip1 was detected only in the cells transfected with wild-type BRCA1 (Figure 3b ). By 35 cycles the p27 Kip1 PCR product was equivalent in all samples (data not shown). Thus these results suggest that the regulation of p27
Kip1 by BRCA1 is transcriptional.
Identification of a putative BRCA1-responsive element in the p27
These results suggested that the p27 Kip1 promoter contained a putative BRCA1-responsive element. Initial experiments were carried out using deletion mutants of the mouse p27
Kip1 promoter. Deletion up to position 7774 increased the activity of BRCA1 on the p27
Kip1 promoter reporter constructs (Figure 4a ), which is consistent with a previous report showing that the mouse p27
Kip1 promoter contains negative regulatory elements in the region 71609 to 7925 (Kwon et al., 1996) . Further deletion to 7615 did not signi®cantly decrease the response of the p27 Kip1 promoter to BRCA1 (Figure 4a ). However, BRCA1 responsiveness was lost by deletions up to position 7511. These results suggested that a putative BRCA1-responsive element was located between positions 7615 and 7511 of the p27
Kip1 promoter. BLAST analysis determined that this region of the mouse p27
Kip1 promoter (7774 to the translation start site) was 94% identical to this region of the human p27
Kip1 promoter, which starts at position 7943.
Subsequent transient transfection assays with deletion mutants of the human p27
Kip1 promoter demonstrated that the putative BRCA1-responsive element identi®ed in the mouse p27
Kip1 promoter was located to the same region of the human p27
Kip1 promoter, position 7784 to 7680 (data not shown).
These results in conjunction with the immunoblot analysis of the breast cancer cell lines suggest that the eect of BRCA1 on p27
Kip1 is p53-independent. The correlation of BRCA1 and p27
Kip1 protein expression was observed in breast cancer cell lines expressing either wild-type p53 (MCF7) or mutant p53 (MDA-MB-231, T-47D). Also the putative p53 elements in the p27
Kip1 promoter are 5' to position 7774, the p27 Kip1 promoter deletion construct having the greatest induction by co-transfection with BRCA1 ( Figure 4b ). However these results do not determine whether p27
Kip1 activation by BRCA1 is a direct or indirect eect by BRCA1. To investigate the eect of BRCA1 on the p27
Kip1 promoter we generated oligonucleotides spanning the region of the mouse promoter containing the putative BRCA1-responsive element as identi®ed by the promoter deletion analysis. These oligonucleotides (oligo A 7609 to 7575, oligo B 7577 to 7543, oligo C 7545 to 7511) were used in EMSA with nuclear lysates from two breast cancer cell lines MCF7 and HCC1937, a breast cancer cell line which is unizygous for the BRCA1 5382insC mutation, resulting in termination of BRCA1 protein translation at codon 1829 (Tomlinson et al., 1998) . Nuclear extract from MCF7 produced a slowly migrating band with oligo C but did not show any signi®cant binding to oligo A or oligo B (Figure 4b ). In contrast, nuclear extract from HCC1937 did not produce a band shift with any of the oligonucleotides (Figure 4b and data not shown). Subsequently we determined by immunohistochemistry that HCC1937 did express BRCA1 protein (Figure 5b) .
The slowly migrating complex observed with MCF7 nuclear extract and oligo C could be competed 90% by a 10-fold excess of cold oligo C (Figure 4b ). Some competition was observed with cold oligo A but there was no competition observed with an excess of an unrelated oligo (oligo U; STAT site from MUC1 promoter). This suggests that the DNA-protein complex is speci®c.
BRCA1 has been shown to interact with a number of other proteins. We used a number of antibodies in the EMSAs to determine the proteins involved in the slowly migrating complex. Of all the antibodies tested, only an antibody against exon 11 of BRCA1 resulted in a supershifting of the complex (Figure 4b ). The antibody against the C-terminus of BRCA1 decreased the protein-DNA complex by 40 ± 50%, suggesting that this antibody might interfere with BRCA1 binding to Reverse transcription-PCR demonstrated that both wild-type and mutant BRCA1 were being expressed. Expression of p27
Kip1 was observed only in the cells transfected with wild-type BRCA1. Equality between samples was shown by using primers for GAPDH Figure 4 Region of mouse p27
Kip1 promoter containing the putative BRCA1-responsive element identi®ed by 5' deletion mapping. (a) COS cells were co-transfected with the 5'-deletion p27 Kip1 promoter reporter constructs and either pCR3 or pCR3-BRCA1, and luciferase activity was measured 48 h later. These results represent three independent experiments. (b) Nuclear lysate from MCF7 was incubated with oligo A (7609 to 7575), oligo B (7577 to 7543) and oligo C (7545 to 7511) of the p27 Kip1 promoter. Nuclear lysate from HCC1937 and HCC-BRCA1 was incubated with oligo C. Cold competition was carried out with an excess of oligo C, oligo A or oligo U (an unrelated 35 bp sequence). The complex is supershifted by an antibody against exon 11 of BRCA1. (c) MCF7 cells were transfected with a 5'-deletion p27 Kip1 promoter construct (7774) or with the construct minus the putative BRCA1-responsive element (7774 (del 545-511)). Luciferase activity was measured as in Figure 1 . These results represent three independent experiments the DNA (data not shown). Together these results suggest that BRCA1 is interacting directly with the DNA sequence from the p27 Kip1 promoter. Since nuclear extract from the mutant BRCA1 cell line HCC1937 did not bind the DNA sequence from the p27
Kip1 promoter, we re-introduced wild-type BRCA1 into this cell line (HCC-BRCA1) and repeated the EMSA analysis. In this experiment a slowly migrating complex was observed with oligo C and nuclear extract from HCC-BRCA1 (Figure 4b ). This slowly migrating complex with HCC-BRCA1 was less than that observed for MCF7 but the level of expression of wild-type BRCA1 in HCC-BRCA1 was lower than that observed for MCF7 (data not shown). Thus introduction of wild-type BRCA1 did restore binding to the p27 Kip1 promoter sequence. Since it appeared that the BRCA1-responsive element could be localized to a 35 bp region of the p27 Kip1 promoter, we generated a construct in which this region was deleted. Transient transfection assays using the deletion construct 7774 and the construct without the putative BRCA1-responsive element 7774 (del 545 ± 511) demonstrated that the removal of this 35 bp region decreased BRCA1 responsiveness of the p27 Kip1 promoter by 80% (Figure 4c ). Therefore it does appear that the BRCA1-responsive element is located at position 7545 to 7511 of the mouse p27 Kip1 promoter, which corresponds to 7714 to 7680 of the human p27
Kip1 promoter. This region is 100% identical between the mouse and human promoter.
Previous deletion analysis of the human p27
Kip1 promoter suggested that a region from 7774 to 7435 contained the essential transcription factor binding sites (Minami et al., 1997) .
Decreased p27
Kip1 protein expression in mutant BRCA1-expressing breast cancer cell line Since wild-type BRCA1 increases p27
Kip1 protein levels in contrast to the tumor-associated BRCA1 mutants, we decided to compare the endogenous p27
Kip1 protein levels in cells expressing wild-type BRCA1 (MCF7) versus mutated BRCA1 (HCC1937). Immunohistochemistry demonstrated reactivity of both MCF7 and HCC1937 with an N-terminal BRCA1 antibody (Figure 5a,b) . As expected from our transfection assay results immunoreactivity for p27
Kip1 was weak for the HCC1937 cell line, as compared to MCF7 which showed strong expression of p27
Kip1 protein ( Figure  5c,d) .
Discussion
It has previously been demonstrated that BRCA1 can transcriptionally upregulate p21
Waf1/Cip1 and GADD45 (Somasundaram et al., 1997; Jin et al., 2000) . This study demonstrates another target for BRCA1 transcriptional activation, namely the CDI p27
Kip1 . Wildtype BRCA1 transactivated the p27
Kip1 promoter in a Kip1 indicating that a functional Cterminal transactivation domain of BRCA1 is required for modulating p27 Kip1 . This study suggests that another mechanism for growth inhibition by BRCA1 may be mediated via the upregulation of p27
Kip1 . BRCA1 contains two BRCT motifs within the Cterminal transactivation domain and these BRCT regions are also found in several proteins involved in DNA repair and cell cycle checkpoints. (Koonin et al., 1996; Callebaut and Mornon, 1997) . These BRCT motifs have been shown to bind DNA in a sequence speci®c manner (Halligan et al., 1995; Yamane et al., 2000) . The results shown here suggest that the mutated BRCA1 in HCC1937 cells is not able to bind DNA because the mutation results in a truncated protein lacking intact BRCT domains. Furthermore, an antibody against the C-terminus of BRCA1 decreased the slowly migrating complex observed with the MCF7 nuclear extract by 40 ± 50%. Thus, these results suggest that the tumor-derived BRCA1 mutations may not be able to eciently transactivate gene transcription due to an inability to bind DNA.
The region of the p27 Kip1 promoter containing a putative BRCA1 responsive element was mapped to positions 7545 to 7511 of the mouse or positions 7714 to 7680 of the human p27
Kip1 promoter. A comparison of this region to those identi®ed as being important for BRCA1 regulation of the p21 Waf1/Cip1 promoter (7143 to 793) and the GADD45 promoter (7121 to 775) did not demonstrate any homology between these promoters regarding the identi®ed BRCA1-responsive elements. However, gel mobility shift analysis did demonstrate that all three promoter regions could bind BRCA1, that the complex could be supershifted by an antibody against BRCA1, and that binding to one promoter region could be competed by an excess of the other promoter regions (Williamson, unpublished results) . These studies together suggest that BRCA1 might have dierent target motifs for activation. It has been suggested that another p21 Waf1/Cip1 promoter motif, the STAT binding serum-inducible element can be activated in response to BRCA1 (Ouchi et al., 1998) . Thus the choice of motifs for activation by BRCA1 may vary according to the presence of transcription factors in dierent cell types, as well as other signaling events within the cell.
The p27 Kip1 is decreased in various human cancers but speci®c mutations have only rarely been reported (Spirin et al., 1996) . Transcriptional, translational and post-translational mechanisms contribute to p27 Kip1 regulation. It had been considered that the major mechanism for regulating p27
Kip1 at the protein level was post-translational. However, transcriptional upregulation of p27
Kip1 by the Forkhead transcription factors has been reported recently (Medema et al., 2000) . For breast tumors, this decrease in p27 Kip1 expression might be a re¯ection of a loss of functional BRCA1, resulting either from a mutation in the BRCA1 gene or by methylation of the BRCA1 promoter. Recent studies have shown that decreased expression of p27
Kip1 does indeed correlate either with both the presence of a BRCA1 mutation in breast tumor tissue as well as with BRCA1 promoter methylation (Chappuis et al., 2000; Niwa et al., 2000) . Thus, loss of functional BRCA1 might be expected to result in impaired growth inhibition due to ineective regulation of p27
Kip1 . Therefore, understanding the mechanisms controlling p27
Kip1 expression in breast tumors may provide new strategies to inhibit tumor growth.
Materials and methods
Plasmid constructs
The promoter region of p27
Kip1 and the enzyme generated 5' deletions were subcloned into pGL2-basic as previously described (Kwon et al., 1996; Minami et al., 1997) . These were provided by J Wyke. The p27
Kip1 promoter construct 7774 (del 545 ± 511) was generated by two rounds of PCR and subcloned into the HindII/SacI site of the pGL2 vector. Removal of the 35 bp was con®rmed by sequencing. The pCR3 vectors encoding wild-type BRCA1 and the synthetic and tumor-associated mutants of BRCA1 were constructed as previously described and provided by B Weber (Somasundaram et al., 1997) . The Zn 2+ -inducible BRCA1 was generously provided by J Holt (Abbott et al., 1999) .
Cells, transfections and luciferase assays
All cell lines were obtained from ATCC. COS, MCF7 and HCT116 were transfected using 1 mg of each expression plasmid by Geneporter according to the manufacturer's instructions (Gene Therapy Systems). Lysates were harvested 48 h post-transfection and luciferase assays carried out according to the manufacturer's protocol (Promega). Transfection eciency was normalized using pRL-SV40 at 1/10 of total DNA concentration.
Generation of stably transfected HCC1937 cells
Full-length BRCA1 was ligated into the NotI/HindIII of the pMT vector, which contains a Zn 2+ -inducible promoter and the neomycin resistance gene (Abbott et al., 1999) . HCC1937 was transfected with 1 mg of pMT-BRCA1. Cells were then selected in 50 mg/ml G418 (Sigma) for 4 weeks. Five cell lines were generated and analysed for expression by Western blotting.
Reverse transcription and PCR
HCT116 cells were transiently transfected with either pCR3, pCR3-BRCA1 or pCR3-BRCA1 (Gln1756insC). After 48 h the cells were harvested for RNA using Trizol according to the manufacturer's instructions (Invitrogen). 2.5 mg total RNA was used for reverse transcription followed by 1/50 of the reverse transcription reaction being used for PCR. PCR for BRCA1 and p27
Kip1 was as follows: BRCA1 primers (FOR 5'-GATTTGACGGAAACATCTTAC and REV 5'-CCAGCAGTATCAGTAGTATGA) spanning exons 14 and 15 resulting in a 236 bp product; p27 Kip1 primers (FOR 5'-CCATGTCAAACGTGCGAGTGT and REV 5'-CGTTTGACGTCTTCTGAGG) which give a product of 594 bp. Results were visualized by an ethidium bromide stained agarose gel. Integrity of the RNA was assessed by PCR for GAPDH.
Western blot analysis
Cells were lysed in a buer containing 20 mM Tris-Cl pH 8, 137 mM NaCl, 10% glycerol, 1% Triton X-100, 2 mM EDTA, 1 mM Na 3 VO 4 and protease inhibitors. Lysates were analysed with the following antibodies: 1 : 200 anti-C-terminal BRCA1 (C-20, Santa Cruz), 1 : 500 anti-N-terminal BRCA1 (Ab-1, Calbiochem) and 1 : 2500 monoclonal anti-p27 Kip1 (Transduction Labs). Equal protein loading was determined with an antibody against GAPDH (Research Diagnostics). Results were visualized by Enhanced Chemiluminescence (Amersham).
Nuclear protein preparation and electrophoretic mobility shift assays (EMSA) Double stranded consensus oligonucleotides were end-labeled with g- 
Immunohistochemistry
MCF7 and HCC1937 were harvested, ®xed in 4% formalin and embedded in paran blocks. The sections were analysed with the following antibodies: monoclonal anti-p27 Kip1 (Transduction Labs) and N-terminal BRCA1 (Ab-1, Calbiochem). The positive control for these antibodies was an invasive mammary carcinoma. The negative control for all antibodies was the detection process without the primary antibody. Dilutions were as recommended by the manufacturers. Results were visualized by horseradish peroxidase and assessed by light microscopy.
